Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

Sorafenib, an oral VEGFR-2, Raf, PDGFR, c-KIT and Flt-3 inhibitor, is active against renal cell and hepatocellular carcinomas, and has recently demonstrated promising activity for lung and breast cancers. In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Reardon, David A., Vredenburgh, James J., Desjardins, Annick, Peters, Katherine, Gururangan, Sridharan, Sampson, John H., Marcello, Jennifer, Herndon, James E., McLendon, Roger E., Janney, Dorothea, Friedman, Allan H., Bigner, Darell D., Friedman, Henry S.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3102498/
https://ncbi.nlm.nih.gov/pubmed/20443129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0217-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars